Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alisertib Plus R-EPOCH in Myc-Positive Aggressive B-Cell Lymphomas
NCT02700022Phase 1Terminated
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Oct 2016
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of alisertib in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and Burkitt lymphoma (BL), sponsored by UNC Lineberger Comprehensive Cancer Center. Primary endpoint: Maximum Tolerated Dose at 2 years. Started Oct 2016; status: terminated.
02
Drugs
alisertib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)Burkitt lymphoma (BL)
Beyond the preview
Go deeper on NCT02700022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02700022.